According to the latest data from the Centers for Disease Control and Prevention, Epidiolex is the first drug to treat the Ebola virus and the first one to show efficacy in patients who have not already had a fever.
Epidios, which is a generic of an FDA-approved drug that can be used to treat high blood pressure and other conditions, is available for sale at drugstores, and will be available for use in the U.S. on Tuesday, December 4th.
“With the development of the first Epidiopin-like drug, we have taken the first step towards treating Ebola-related chronic disease,” said Dr. Scott Anderson, president and CEO of Epidias Pharmaceuticals, in a statement.
“This is an important milestone for our team and we are excited to share the latest findings with our team members and their families.
We look forward to continuing to accelerate development and provide patients with the best possible treatment.”
The FDA approved Epidien for use as a treatment for high blood pressures and other ailments that are related to COVID-19.
In February, the agency approved EpiPen to treat pain caused by COVID, and in August the FDA approved two new drugs to treat other serious infections including dengue and yellow fever.
It’s not clear how long the FDA has planned to take to approve the Epidies, but the agency said in October that it would approve the drug as early as the first quarter of 2019.
In a statement, the EpiPens, which cost $300 each, are being sold to a variety of people, including emergency rooms, nursing homes, hospices, and schools.
“The FDA will continue to evaluate the safety and efficacy of these drugs in clinical trials, and may announce additional decisions in the coming weeks,” Anderson said.
“We are excited about the potential of EpiPs as a new tool for treating COVID.”